Profile data is unavailable for this security.
About the company
Blau Farmaceutica SA is a Brazil-based company engaged in the pharmaceuticals sector. The Company focuses on the development, production and commercialization of medicines, which aim at treatment in the areas of oncology, nephrology, hematology and infectology, among others. Its product lines includes biopharmaceuticals, biosimilars, oncological - injectable, oncological - oral, blood products, antiviral and antiretrovirals, uterine stimulators, anaesthetics, antithrombotics, thrombolytics, female health care, antibiotics, non-beta lactams, cephalosporin, chloramphenicol, acid pumper inhibitor and other hospital products. The Company operates in Brazil, Argentina, Colombia, Peru, Uruguay, Chile and the United States, having a pharmaceutical industrial complex composed of five industrial plants, dedicated to the production of biological, biotechnological and oncological medicines, antibiotics, injectable anesthetics and biotechnological inputs.
- Revenue in BRL (TTM)1.77bn
- Net income in BRL316.54m
- Incorporated1987
- Employees1.90k
- LocationBlau Farmaceutica SARodovia Raposo Tavares2833, km 30,5, Barro BrancoCOTIA 06.705-030BrazilBRA
- Phone+55 1 146159400
- Fax+55 1 146159401
- Websitehttps://www.blau.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oncolys Biopharma Inc | 971.47k | -70.04m | 2.38bn | 35.00 | -- | 17.51 | -- | 2,454.48 | -80.66 | -80.66 | 1.11 | 136.64 | 0.0074 | 0.00 | 0.1004 | -- | -53.08 | -53.26 | -58.54 | -60.19 | 0.00 | -- | -7,209.58 | -484.93 | 9.54 | -424.60 | 0.0741 | -- | -9.04 | -38.10 | -22.16 | -- | 2.22 | -- |
| Knight Therapeutics Inc | 1.59bn | -13.38m | 2.39bn | 745.00 | -- | 0.8216 | 12.01 | 1.51 | -0.0378 | -0.0378 | 4.12 | 7.69 | 0.4116 | 1.84 | 3.96 | 555,498.00 | -0.3474 | 0.0976 | -0.4015 | 0.1143 | 42.49 | 46.11 | -0.844 | 0.351 | 1.68 | -- | 0.1217 | 0.00 | 13.13 | 50.90 | 125.73 | -21.48 | 60.58 | -- |
| Eton Pharmaceuticals Inc | 367.36m | -34.91m | 2.39bn | 31.00 | -- | 19.79 | -- | 6.51 | -0.2491 | -0.2491 | 2.63 | 0.8624 | 1.00 | 3.64 | 7.53 | 2,268,258.00 | -9.52 | -27.81 | -17.48 | -37.96 | 51.36 | 68.16 | -9.50 | -38.41 | 1.25 | 0.2114 | 0.5677 | -- | 23.29 | 109.83 | -308.44 | -- | 40.24 | -- |
| GuiZhou YiBai Pharmaceutical Co., Ltd. | 1.44bn | -177.43m | 2.40bn | 5.26k | -- | 1.32 | -- | 1.67 | -0.3003 | -0.3003 | 2.42 | 3.03 | 0.4764 | 1.43 | 9.21 | 362,458.80 | -6.27 | -0.973 | -8.33 | -1.31 | 58.70 | 72.00 | -13.17 | -1.65 | 1.25 | -10.11 | 0.2733 | -- | -22.92 | -8.34 | -406.79 | -- | -13.70 | -- |
| Ginwa Enterprise Group Inc | 416.25m | 59.23m | 2.42bn | 588.00 | 39.82 | 2.02 | -- | 5.83 | 0.2157 | 0.2157 | 1.54 | 4.24 | 0.2885 | 4.56 | 4.97 | 936,120.60 | 4.04 | 0.839 | 4.86 | 0.9762 | 76.30 | 75.14 | 14.00 | 2.83 | 1.84 | -- | 0.0561 | 52.12 | 3.55 | -4.95 | 273.96 | 23.56 | 28.32 | 0.00 |
| Blau Farmaceutica SA | 1.77bn | 316.54m | 2.44bn | 1.90k | 7.49 | 1.03 | 6.40 | 1.38 | 1.39 | 1.39 | 7.59 | 10.17 | 0.5156 | 1.68 | 3.45 | -- | 9.22 | 12.47 | 11.00 | 14.84 | 40.23 | 42.91 | 17.89 | 19.76 | 1.85 | 41.28 | 0.1893 | 16.42 | 27.81 | 12.41 | -13.05 | 1.64 | 24.25 | -- |
| YungShin Global Holding Corp | 1.39bn | 160.41m | 2.45bn | 1.57k | 15.30 | 1.89 | 11.14 | 1.76 | 3.61 | 3.61 | 31.42 | 29.23 | 0.6584 | 1.62 | 6.24 | -- | 8.04 | 7.42 | 11.09 | 10.99 | 43.33 | 44.54 | 12.21 | 11.84 | 2.14 | 27.06 | 0.1236 | 69.00 | 14.29 | -0.3928 | 41.24 | 9.31 | -18.32 | 6.40 |
| Shanghai Shenqi Pharmactcl Inv Mgt CoLtd | 1.42bn | 47.14m | 2.45bn | 1.27k | 53.70 | 1.46 | -- | 1.72 | 0.1186 | 0.1186 | 3.58 | 4.37 | 0.5981 | 4.66 | 5.41 | 1,487,675.00 | 1.85 | -0.6947 | 2.33 | -0.8656 | 44.60 | 53.83 | 3.10 | -1.04 | 2.57 | 31.84 | 0.0745 | -- | -12.48 | 1.23 | 25.24 | -3.20 | -13.91 | -- |
| Elite Pharmaceuticals Inc | 642.04m | 72.74m | 2.47bn | 68.00 | 36.07 | 7.67 | 30.39 | 3.85 | 0.0122 | 0.0122 | 0.1131 | 0.0574 | 1.20 | 3.60 | 3.94 | 1,807,255.00 | 13.55 | 13.18 | 15.31 | 16.01 | 52.66 | 47.19 | 11.33 | 13.97 | 6.34 | 2.37 | 0.0681 | 0.00 | 48.42 | 36.10 | -121.46 | -- | 135.38 | -- |
| ASKA Pharmaceutical Holdings Co Ltd | 2.34bn | 166.99m | 2.47bn | 1.63k | 14.60 | 1.04 | 9.37 | 1.06 | 172.92 | 172.92 | 2,421.07 | 2,420.68 | 0.6729 | 1.37 | 3.62 | 42,094,980.00 | 4.93 | 5.50 | 6.64 | 7.07 | 48.33 | 47.56 | 7.32 | 7.98 | 1.23 | 75.35 | 0.1551 | 16.60 | 2.06 | 4.07 | -32.39 | 51.04 | 9.49 | 31.48 |
Data as of Feb 14 2026. Currency figures normalised to Blau Farmaceutica SA's reporting currency: Brazilian Real BRL
4.03%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Vokin Administra��o de Recursos LTDAas of 30 Sep 2025 | 5.12m | 2.20% |
| BTG Pactual Gest�o E Consultoria De Investimentos Ltda.as of 30 Sep 2025 | 2.21m | 0.95% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 546.52k | 0.23% |
| Exploritas Administra��o Financeira Ltda.as of 30 Sep 2025 | 297.18k | 0.13% |
| BlackRock Brasil Gestora de Investimentos Ltda.as of 05 Feb 2026 | 273.85k | 0.12% |
| Mellon Investments Corp.as of 06 Feb 2026 | 232.54k | 0.10% |
| Banco BTG Pactual SA (Investment Management)as of 30 Sep 2025 | 205.40k | 0.09% |
| Apo Asset Management GmbHas of 31 Mar 2024 | 194.74k | 0.08% |
| Verde Asset Management SAas of 30 Sep 2025 | 169.52k | 0.07% |
| Hix Investimentos Ltda.as of 30 Sep 2025 | 152.10k | 0.07% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
